We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Ignore the pain

2 April 2004 By Robert Cyran

The Swiss drugs company could create more value in a merger than Sanofi as it could cut more costs. An offer of E66 per share would be 17% higher than Sanofi s bid and still leave value for the Swiss.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)